Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug2176	Saline Wiki	0.38

Correlated MeSH Terms (3)

---

	Name (Synonyms)	Correlation
D009877	Endophthalmitis NIH	1.00
D002481	Cellulitis NIH	1.00
D054517	Orbital Cellulitis NIH	1.00

Correlated HPO Terms (1)

---

	Name (Synonyms)	Correlation
HP:0100658	Cellulitis HPO	1.00

Primary Outcomes

Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.

Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.

Time: 15 days

---

Secondary Outcomes

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces time to clinical improvement as defined by a decline of 2 categories or more from the baseline on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients or hospital discharge whichever comes first.

Measure: Time to clinical improvement

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces inpatient mortality.

Measure: Inpatient mortality

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of hospitalization.

Measure: Duration of hospitalization

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of intubation for mechanical ventilation.

Measure: Duration of intubation for mechanical ventilation.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the time to normalization of temperature (T < 37.5 for 48 hours)

Measure: Time to normalization of temperature.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the maximum severity of COVID-19 illness based on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients. Score range 1-7, higher scores equals worse outcome.

Measure: Maximum severity of COVID19 illness.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

---

Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.

Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.

Time: 30 days

---